Nonionic Surfactant Vesicles (Niosomes) of Cytarabine Hydrochloride for Effective Treatment of Leukemias: Encapsulation, Storage, and In Vitro Release

2000 ◽  
Vol 26 (2) ◽  
pp. 217-222 ◽  
Author(s):  
K. Ruckmani ◽  
B. Jayakar ◽  
S. K. Ghosal
Keyword(s):  
Nonionic Surfactant ◽  
Effective Treatment ◽  
In Vitro Release ◽  
Surfactant Vesicles ◽  
Nonionic Surfactant Vesicles ◽  
Vitro Release

scholarly journals Formulation and Characterization of Drug Loaded Nonionic Surfactant Vesicles (Niosomes) for Oral Bioavailability Enhancement

2014 ◽  
Vol 2014 ◽  
pp. 1-8 ◽  
Author(s):  
Sunil Kamboj ◽  
Vipin Saini ◽  
Suman Bala
Keyword(s):  
Nonionic Surfactant ◽  
Oral Bioavailability ◽  
Release Kinetics ◽  
Prolonged Release ◽  
Bioavailability Enhancement ◽  
Surfactant Vesicles ◽  
Nonionic Surfactant Vesicles ◽  
Dicetyl Phosphate

Nonionic surfactant vesicles (niosomes) were formulated with an aim of enhancing the oral bioavailability of tenofovir disoproxil fumarate (TDF), an anti-HIV drug. Niosomes were formulated by conventional thin film hydration technique with different molar ratios of surfactant, cholesterol, and dicetyl phosphate. The formulated niosomes were found spherical in shape, ranging from 2.95 μm to 10.91 μm in size. Vesicles with 1 : 1 : 0.1 ratios of surfactant : cholesterol : dicetyl phosphate with each grade of span were found to have higher entrapment efficiencies, which were further selected forin vitroandin vivostudies. Vesicles formulated with sorbitan monostearate were found to have maximum drug release (99.091%) at the end of 24 hours and followed zero order release kinetics. The results ofin vivostudy revealed that the niosomes significantly enhanced the oral bioavailability of TDF in rats after a dose of 95 mg/kg. The average relative bioavailability of niosomes in relation to plane drug solution was found to be 2.58, indicating more than twofold increase in oral bioavailability of TDF. Significant increase in mean residential time (MRT) was also found, reflecting release retarding efficacy of the vesicles. In conclusion, niosomes could be a promising delivery for TDF with improved oral bioavailability and prolonged release profiles.

scholarly journals Nonionic Surfactant Vesicles Composed of Novel Spermine-Derivative Cationic Lipids as an Effective Gene Carrier In Vitro

2014 ◽  
Vol 15 (3) ◽  
pp. 722-730 ◽  
Author(s):  
Orapan Paecharoenchai ◽  
Nattisa Niyomtham ◽  
Lalita Leksantikul ◽  
Tanasait Ngawhirunpat ◽  
Theerasak Rojanarata ◽  
...  
Keyword(s):  
Nonionic Surfactant ◽  
Cationic Lipids ◽  
Gene Carrier ◽  
Surfactant Vesicles ◽  
Nonionic Surfactant Vesicles

scholarly journals Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown

2019 ◽  
Vol 29 (3) ◽  
pp. 229-238 ◽  
Author(s):  
Mohammad A. Obeid ◽  
Christine Dufès ◽  
Sukrut Somani ◽  
Alexander B. Mullen ◽  
Rothwelle J. Tate ◽  
...  
Keyword(s):  
Nonionic Surfactant ◽  
Sirna Delivery ◽  
Proof Of Concept ◽  
In Vivo Evaluation ◽  
Surfactant Vesicles ◽  
Nonionic Surfactant Vesicles

Study on in vitro release patterns of fentanyl-loaded PLGA microspheres

2003 ◽  
Vol 20 (5) ◽  
pp. 569-579 ◽  
Author(s):  
S.-A. Seo ◽  
G. Khang ◽  
J. M. Rhee ◽  
J. Kim ◽  
H. B. Lee
Keyword(s):  
In Vitro Release ◽  
Plga Microspheres ◽  
Vitro Release

Reliability of a Single β-Thromboglobulin Measurement in a Diabetic Population : Importance of PGE1 in Anticoagulant Mixture

1987 ◽  
Vol 57 (02) ◽  
pp. 201-204 ◽  
Author(s):  
P Y Scarabin ◽  
L Strain ◽  
C A Ludlam ◽  
J Jones ◽  
E M Kohner
Keyword(s):  
In Vitro Release ◽  
Mean Value ◽  
Reliable Estimate ◽  
Diabetic Patients ◽  
Single Measurement ◽  
Diabetic Population ◽  
The Difference ◽  
Vitro Release

SummaryDuring the collection of samples for plasma β-thromboglobulin (β-TG) determination, it is well established that artificially high values can be observed due to in-vitro release. To estimate the reliability of a single β-TG measurement, blood samples were collected simultaneously from both arms on two separate occasions in 56 diabetic patients selected for a clinical trial. From each arm, blood was taken into two tubes containing an anticoagulant mixture with (tube A) and without (tube B) PGE!. The overall mean value of B-TG in tube B was 1.14 times higher than in tube A (p <0.01). The markedly large between-arms variation accounted for the most part of within-subject variation in both tubes and was significantly greater in tube B than in tube A. Based on the difference between B-TG values from both arms, the number of subjects with artifically high B-TG values was significantly higher in tube B than in tube A on each occasion (overall rate: 28% and 14% respectively). Estimate of between-occasions variation showed that B-TG levels were relatively stable for each subject between two occasions in each tube. It is concluded that the use of PGEi decreases falsely high B-TG levels, but a single measurement of B-TG does not provide a reliable estimate of the true B-TG value in vivo.

Preparation and In-vitro Evaluation of Fe3O4 Encapsulated by Chitosan Loaded Capecitabine Nanoparticles for the Treatment of Breast Cancer

2016 ◽  
Vol 6 (3) ◽  
Author(s):  
Shanmuganathan S. ◽  
Nigma S. ◽  
Anbarasan B. ◽  
Harika B.
Keyword(s):  
Fe3o4 Nanoparticles ◽  
Polymer Concentration ◽  
In Vitro Release ◽  
Entrapment Efficiency ◽  
In Vitro Evaluation ◽  
Sem Image ◽  
Therapeutic Molecules ◽  
Dialysis Method ◽  
Vitro Release

Nanoparticulate Carriers which is biodegradable, biocompatible and bio adhesive have significant feasible applications for administration of therapeutic molecules. The present study was aimed to formulate and optimise Capecitabine loaded Chitosan-Fe3O4 Nanoparticles and to study the in-vitro evaluation by sigma dialysis method. Capecitabine loaded chitosan – Fe3O4 nanoparticles batches with different ratios of drug: polymer (1:1, 1:2, 1:3, 1:4, 1:5, 1:6) were prepared by ionic gelation method. Increase in polymer concentration increases the nanoparticle drug content. Entrapment efficiency was 60.12% with drug to polymer ratio F3 (1:3). In-vitro release was found to be 65.20% for 12 hrs. Capecitabine from chitosanFe3O4 nanoparticles SEM image reveals discrete spherical structure and particles with size range of 100-500nm. FTIR studies represent the functional groups present with no characteristics change in formulations. Samples stored at refrigerator conditions showed better stability compared with samples kept at other conditions during 8 weeks of storage.

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

2015 ◽  
Vol 5 (3) ◽  
Author(s):  
Laxman Devkota ◽  
Bhupendra Poudel ◽  
Junu Silwal
Keyword(s):  
In Vitro Release ◽  
Magnesium Stearate ◽  
Physical Parameters ◽  
Artificial Sweetener ◽  
Leukotriene Receptor Antagonist ◽  
Montelukast Sodium ◽  
Chewable Tablets ◽  
Leukotriene Receptor ◽  
Vitro Release

The objective of the present study is to develop chewable tablets containing different pharmaceutical compositions with simple manufacturing procedures using different excipients. Mannitols, L-HPC 11, Aspartame, Crospovidone, Crospovidone, Aerosil, and Magnesium Stearate are used as excipients for effective formulation of anti-asthmatic drug Montelukast. Montelukast is a selective, orally acting leukotriene receptor antagonist that is used for the treatment of asthma and seasonal allergic rhinitis. Montelukast chewable tablets were prepared by Direct Compression methods using suitable excipients. The chewable tablets were better presented using artificial sweetener Aspartame as flavouring agent. A total of forteen formulations were prepared and the granules were evaluated for pre-compression parameters. The formulated tablets were evaluated for post-compression parameters .The results showed that all the physical parameters were within the acceptable limits. The in vitro release study of all the formulations showed good release. The study concludes that aforementioned excipients can be used to design chewable montelukast sodium tablets.

Sign in / Sign up

Export Citation Format

Share Document